These data are consistent with a recent study showing improved skeletal muscle oxidative enzyme activity and restoration of PGC-1α gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes [40]. Here, PPARGC1A is linked to type 2 diabetes mellitus.